

Devgen NV

Limited Liability Company
Technologiepark 30
9052 Gent-Zwijnaarde
Register of Legal Persons – Enterprise number 0461.432.562

Report of the Board of Directors in accordance with Articles 596 and 598 of the Belgian Company Code

1. Articles 596 and 598 of the Belgian Company Code

This special report has been prepared by the board of directors of the limited liability company (*naamloze vennootschap (NV)/société anonyme (SA)*) “Devgen” (the “Company”) in accordance with Article 596 of the Belgian Company Code. The report relates to the issuance, by the extraordinary general shareholders' meeting, of:

(i) 750.000 (naked) warrants in the framework of a warrant plan substantially for employees of the Company and its subsidiaries (and future subsidiaries, if any), with cancellation of the preferential subscription right of the existing shareholders to the benefit of substantially employees and in secondary order the consultants and the CEO of the Company and its subsidiaries (and future subsidiaries, if any) (“Plan Employees/CEO/Consultants”).

(ii) 11.724 (naked) warrants in the framework of a warrant plan for directors of the Company, with cancellation of the preferential subscription rights of the shareholders of the Company to the benefit of the independent directors of the Company (“Plan Directors”).

In accordance with Article 596 and Article 598 of the Belgian Company Code, the Board of Directors further discusses in the present report the cancellation of the preferential subscription rights of the existing shareholders of the Company, the proposed issuance price of the warrants and the financial consequences of the transaction for the existing shareholders of the Company.

This report must be read together with the report that was prepared by the statutory auditor of the Company in accordance with Article 596 and 598 of the Belgian Company Code relating to the proposed cancellation of the preferential subscription rights of the shareholders of the Company. It must also be read with the special report of the board of directors that was prepared in accordance with Article 583 of the Belgian Company Code relating to the proposed issuance of the warrants.

2. Proposed transaction

The board of directors proposes to issue 761,724 (naked) warrants. Each warrant shall give the right to subscribe to one new share of the Company, against payment of an exercise price in cash.

The proposed issuance of the warrants involves a capital increase under condition precedent since, to the extent the warrants are exercised, the share capital of the Company will be increased and new shares will be issued (see also below).

The Board of Directors proposes to an extraordinary general shareholders' meeting to issue the warrants.

As set forth in the special report of the board of directors in accordance with article 583 of the Belgian Company Code, the proposed issuance of the warrants forms part of two warrant plans: the first substantially for employees of the Company and its subsidiaries and, in secondary order, for the consultants and directors of the Company and its subsidiary (and future subsidiaries, if any), and the second for the independent directors of the Company. In order to be able to offer the warrants in accordance with the proposed issuance conditions of the warrant plan, the board of directors proposes to cancel the preferential subscription right of the existing shareholders of the Company for the benefit of the above mentioned categories of participants to the plans.

1) Plan Employees/CEO/Consultants

Below, an overview is given of the possible participants who are not employees of the Company and its subsidiaries and who will participate in secondary order to the Plan Employees/CEO/Consultants:

- BVBA Thierry Bogaert / Mr. Thierry Bogaert
- BVBA Hilde Windels /Ms. Hilde Windels
- Robert Ackerson
- Thomas Brown
- Stefan Frey
- Michael Goutama
- Tom Hashman
- Gurdev Kush
- John Mann
- Peter Snauwaert

For a description of the proposed issuance and exercise conditions of the warrants reference is made to the special report of the board of directors in accordance with article 583 of the Belgian Company Code.

2) Plan Directors

Below, the names are mentioned of the independent directors who qualify for a grant of warrants by subscription to the warrants at the occasion of the issuance that is proposed to the extraordinary general shareholders' meeting.

- Pol Bamelis NV
- Jan Leemans
- Remi Vermeiren
- Alan Williamson

3. Justification of the transaction

3.1. *Cancellation of the preferential subscription right*

The proposed cancellation of the preferential subscription right is necessary in order to be able to offer the warrants to employees and, in secondary order, to directors and consultants of the Company and its subsidiary/(ies) under the Plan Employees/CEO/Consultants. The board of directors is of the opinion that such cancellation is justified because the warrants are issued in the framework of new warrant plans for employees, the CEO, Consultants and independent directors of the Company and its subsidiary/(ies). As further explained in its report in accordance with article 583 of the Belgian Company Code, the board of directors is of the opinion that this plan is in the interest of the Company.

3.2. *The exercise price of the warrants*

1) Plan Employees/CEO/Consultants

The new shares that will be issued upon exercise of the warrants under the Plan Employees/CEO/Consultants, shall be issued at a price per share as determined by the Company's Nomination and Remuneration Committee. The exercise price has not yet been determined at this moment but will be determined upon the offer of the warrants as set forth below:

- When a warrant is offered to an employee of the Company or its subsidiary, the exercise price must at least be equal to:
 - the average of the closing prices of the shares of the Company as listed on the Eurolist by Euronext of Euronext Brussels (or any other regulated or public market on which the shares of the Company will then be listed or traded) during the thirty (30) day period (or any other relevant period) preceding the offer by the Nomination and Remuneration Committee to the selected participant; or
 - the closing price of the shares of the Company as listed on the Eurolist by Euronext of Euronext Brussels (or any other regulated or public market on which the shares of the Company will then be listed or traded) on the day preceding the day of the offer to the selected participant.

- When a warrant is offered to the CEO or to a consultant of the Company or its subsidiary, the exercise price must at least be equal to the highest amount of either:
 - the average of the closing prices of the shares of the Company as listed on the Eurolist by Euronext of Euronext Brussels during the thirty (30) day period preceding the issuance of the warrants by the Company's extraordinary general shareholders' meeting, and
 - at the option of the Nomination and Remuneration Committee, one of the following amounts:
 - (a) the average of the closing prices of the shares of the Company as listed on the Eurolist by Euronext of Euronext Brussels (or any other regulated or public market on which the shares of the Company will then be listed or traded) during the thirty (30) day period (or any other relevant period) preceding the offer by the Nomination and Remuneration Committee to the selected participant, and
 - (b) the closing price of the shares of the Company as listed on the Eurolist by Euronext of Euronext Brussels (or any other regulated or public market on which the shares of the Company will then be listed or traded) on the day preceding the day of the offer to the selected participant.

2) Plan Directors

The new shares that will be issued upon exercise of the warrants under the Plan Directors, shall be issued at a price per share as determined by the Company's Nomination and Remuneration Committee. The exercise price has not yet been determined at this moment but will be determined upon the offer of the warrants as set forth below:

- the average of the closing prices of the shares of the Company as listed on the Eurolist by Euronext of Euronext Brussels during the thirty (30) day period preceding the issuance of the warrants by the extraordinary general shareholders' meeting of the Company.

The exercise price of the warrants, as determined above, is also determined in accordance with the applicable Belgian tax regime and the Belgian Company Code.

4. Financial consequences of the transaction for the shareholders

The financial consequences of the transaction for the existing shareholders of the Company are set forth below.

4.1. General – The exercise of the warrants

Unless the board of directors provides for additional exercise periods, the warrants can only be exercised annually during their term, between March 16 and March 31 and between September 16 and September 30, provided and to the extent that they have become vested warrants and provided and to the extent that they have become exercisable as further explained in the special report of the board of directors in accordance with article 583 of the Belgian Company Code. Whether a warrant (that has become a vested warrant and has become exercisable) will eventually be exercised depends upon the decision of the holder of the warrant. The exercise of the warrant is not obliged, nor automatic. The exercise of the warrant will normally also depend upon the stock exchange price of the shares of the Company at the moment of exercise of the warrant, if any, since the holder of the warrant can in principle realize a capital gain only upon the exercise of the warrants if the stock exchange price of the shares of the Company at the moment of exercise is higher than the exercise price of the warrants (see also below, section 4.6).

4.2. Evolution of the share capital

At the date of this report, the Company's share capital amounts to €1,341,110.15, represented by 17,881,500 shares without nominal value. Furthermore, the Company has also a number of outstanding warrants.

If the warrants are exercised, the share capital shall be increased through the issuance of new shares in the company since, upon the exercise of a warrant, the share capital of the Company is increased by an amount equal to the exercise price of the warrants. To the extent the exercise price per share to be issued exceeds the fractional value of the then existing shares of the Company, the balance of the exercise price shall be booked as an issuance premium. The issuance premium, if any, will, to the same extent as the Company's share capital, serve as a guarantee for third parties and will be booked on an unavailable account that can only be decreased or booked away by means of a resolution of the general shareholder's meeting passed in the manner required for an amendment of the Company's Articles of Association.

The precise evolution of the capital as a result of the exercise of the warrants will depend upon whether the warrants will be exercised and upon the amount of the fractional value of the shares at the moment of the exercise of the warrants. As mentioned above, the exercise of warrants is not obliged, nor automatic. Therefore, there is no certainty whether the warrants will be exercised.

4.3. Impact on the number of outstanding shares

The table below sets forth an overview of the financial instruments, whether or not representing the share capital, that have been issued by Devgen NV up to April 7, 2008. This overview must be read together with the notes set forth thereunder

Table 1 – Outstanding shares and other financial instruments

	<u>Voting Rights</u>	<u>Notes</u>
(A) Actual voting rights attached to:		
Shares representing the share capital	17.881.500	

	<u>Voting Rights</u>	<u>Notes</u>
(B) Potential future voting rights attached to shares representing the share capital, to be issued upon:		
Exercise of the warrants for employees (1999)	0	(1)
Exercise of the warrants for directors and consultants (1999)	3.995	(1)
Exercise of the CSHL warrants	8.938	(2)
Exercise of the GHC warrants	0	(3)
Exercise of the Warrants 2000	17.896	(4)
Exercise of the TLL warrants	0	(5)
Exercise of the Warrants 2005	298.961	(4)
	329.790	
Total (A)+(B)	18.211.290	
(C) Additional comments: Potential future voting rights attached to the shares representing the share capital to be issued upon:		
Exercise of warrants for employees (1999), which have not yet vested, and which are still conditional	0	(1)
Exercise of warrants for directors and consultants (1999), which have not yet vested, and which are still conditional	0	(1)
Exercise of the CSHL Warrants	0	(2)
Exercise of the TLL Warrants which can still be granted	26.445	(3)
Exercise of Warrants 2000, which have not yet vested, and which are still conditional	4.451	(4)
Exercise of the GSH Warrants which can still be granted	32.667	(5)
Exercise of Warrants 2005, which have not yet vested, and which are still conditional, or which can still be granted	195.713	(4)
	259.276	
Total (A)+(B)+(C)	18.470.566	

Notes:

- (1) Warrants for employees (1999) and warrants for directors and consultants (1999): The warrants have a term of 10 years as of their issuance on September 27, 1999. The warrants were created in the framework of a stock based incentive plan, one for employees and one for directors and consultants of the Company and its subsidiaries. When warrants are offered to a participant in the framework of the plans, the warrants are generally only definitively acquired ("vested") following a certain period after the grant and subject to certain conditions. For instance, the participant must have continued his employment agreement, its mandate as director or its consultancy agreement. Subject to certain conditions, warrants can lapse in the event of termination of the employment agreement, the director's mandate or the consultancy agreement of the participant. Under certain conditions, the Company has a call option on vested warrants in the event of termination of the employment agreement, the director's mandate or the consultancy agreement of the participant. The exercise price of the call option is equal to the warrant price. The call option is transferable
- (2) CSHL warrants: The warrants have a term of 10 years as of December 21, 1999.
- (3) GHC warrants: The warrants have a term of 10 years as of December 21, 1999.
- (4) Warrants 2000 and Warrants 2005: The Warrants 2000 have a term of 10 years as of their issuance on September 22, 2000. The Warrants 2005 have a term of 10 years as of their issuance on December 12, 2005. The warrants were created in the framework of a stock based incentive plan for employees, directors and consultants of the Company and its subsidiaries. When warrants are offered to a participant in the framework of the plan, the warrants are generally only definitively acquired ("vested")

following a certain period after the grant and subject to certain conditions, such as that the participant has continued his mandate as director, or his employment or consultancy agreement. Subject to certain conditions, warrants can lapse in the event of termination of the director's mandate or the employment or the consultancy agreement of the participant. Under certain conditions, the Company has a call option on vested warrants 2000 in the event of termination of the director's mandate or employment or consultancy agreement of the participant. The exercise price of the call option is equal to the warrant price. The call option is transferable

(5) TLL warrants: The warrants have a term of 5 years as of June 1, 2004.

Upon the exercise of the warrants, an additional number of shares will need to be issued. The dilution of each of the existing shares as to its voting rights and of its rights to participate in the profits of the Company, if any, such as preferential subscription rights, liquidation rights, and other rights, is illustrated below in Table 2. It is assumed that all new warrants will be exercised

Table 2 – Simulation of dilution

	Based on the number of outstanding shares prior to the exercise of existing warrants	Based on the number of outstanding shares after the exercise of all existing warrants
Outstanding shares	17.881.500	18.470.566
Shares upon exercise of all Warrants Employees, Consultants and CEO 2008	750.000	750.000
Subtotal.....	18.631.500	19.220.566
Dilution	4,03%	3,90%
Shares upon exercise of all Warrants Directors 2008	11.724	11.724
Subtotal.....	17.893.224	18.482.290
Dilution	0,06%	0,06%
Shares upon exercise of all Warrants Employees, Consultants and CEO 2008 <u>and all Warrants Directors</u> 2008.....	761.724	761.724
Total.....	18.643.224	19.232.290
Total dilution.....	4,09%	3,96%

4.4. Evolution of certain rights attached to the shares

Currently, each share entitles the holder thereof to one vote and all shares participate equally in the profits of the Company, if any, in the same proportion. Furthermore, every share gives the right on an equal basis to a preferential subscription right in case of a capital increase in cash (if this preferential subscription right is not cancelled or limited) and a right to participate equally in the liquidation proceeds in case of liquidation of the Company. To the extent that new shares are issued upon the exercise of the warrant, these shares will have the same voting rights, dividend rights, preferential subscription rights and liquidation rights as the existing shares. As a consequence, there will be a dilution of the relative value of each of the voting rights, dividend rights, preferential subscription rights and liquidation rights of the existing shares. See also the simulation in Table 2 above.

4.5. Evolution of the participation in the accounting net equity

The statutory net equity of the Company on December 31, 2007 amounted to €66,5 million and the consolidated net equity of the Company on the same date amounted to €64,8 million. Since

the Company had 17,956,351 outstanding shares on the above-mentioned date, the participation of each share in the statutory net equity (calculated as the amount of the statutory net equity divided by the number of outstanding shares) on December 31, 2007 amounted to (rounded) €3.72 and the participation of each share in the consolidated net equity (calculated as the amount of the consolidated net equity, divided by the number of outstanding shares) amounted to (rounded) €3.63.

Without taking into account the changes in the statutory, respectively consolidated net equity of the Company since December 31, 2007, the following can be noted. If the exercise price of the warrants under the Plan Employees, CEO and Consultants or under the Plan Directors is higher than the participation of each share in the statutory, respectively consolidated net equity of the Company, then the exercise of a warrant under one of these plans will result, from a pure accounting point of view, in an immediate financial dilution to the benefit of the existing shareholders. On the other hand, if the exercise price of the warrants under one of these plans is lower than the participation of each share in the statutory, respectively consolidated net equity of the Company, then the exercise of a warrant will result, from a pure accounting point of view, in an immediate financial dilution to the detriment of the existing shareholders. If the exercise price of the warrants under one of these plans is equal to the participation of each share in the statutory, respectively consolidated net equity of the Company, hypothetically, no financial dilution occurs.

On the date of this report, the exercise price of the warrants is not yet known since it will be determined at the moment of the offer of the warrants. In addition, it is not certain that all warrants will be exercised. Consequently, it is currently not possible to calculate accurately the impact of the exercise of the warrants, be it under the Plan Employees, CEO and Consultants or under the Plan Directors, on the participation of each share in the (statutory or consolidated) net equity of the Company.

Nevertheless, for information purposes only, the evolution of the statutory and consolidated net equity has been simulated in Table 3 below on the basis of a hypothetical exercise price of the warrants of **€13.00**. This simulation has to be read together with the respective notes set forth under the table.

Table 3 – Simulation of the impact on net equity

	Statutory Net Equity	Consolidated Net Equity
Net equity on December 31, 2007:		
Net Equity	€66.500.000	€64.800.000
Number of outstanding shares	17.881.500	17.881.500
Participation of each share in the net equity	€3,72	€3,62
Issuance of all warrants under the Plan Employees, CEO and Consultants:		
Increase of Net Equity	€9.750.000	€9.750.000
Net Equity	€76.250.000	€74.550.000
Number of issued shares	750.000	750.000
Number of outstanding shares	18.631.500	18.631.500
Participation of each share in the net equity	€4,09	4,00€
Issuance of all warrants under the Plan Directors:		
Increase of Net Equity	€152.412	€152.412
Net Equity	€66.652.412	€64.952.412
Number of issued shares	11.724	11.724
Number of outstanding shares	17.893.224	17.893.224
Participation of each share in the net equity	€3,73	3,63€
Issuance of all warrants under both plans:		
Increase of Net Equity	€9.902.412	€9.902.412
Net Equity	€76.402.412	74.702.412€
Number of issued shares	761.724	761.724
Number of outstanding shares	18.643.224	18.643.224
Participation of each share in the net equity	€4.10	4.01€

Notes:

- (1) The results as of December 31, 2007 of the Company and of the group to which the Company belongs, were not taken into account. The possible effects of a capital increase upon the exercise of the existing outstanding warrants have also not been taken into account.
- (2) As mentioned above, the calculation of the increase in net equity upon exercise of the warrants that are the subject of this report is based on a hypothetical exercise price of €13.00. This exercise price is used for illustration purposes only. This exercise price does not reflect any opinion of the board of directors with respect to the current stock exchange price of the Company's shares. There is no guarantee that the final exercise price will be at the level of the aforementioned exercise price.
- (3) It is assumed that the warrants that are the subject of this report will be exercised immediately upon their issuance, regardless of the applicable conditions. If the warrants are exercised at a later moment, the changes of the net equity of the Company after December 31, 2007 should also be taken into account.

4.6. Other forms of dilution

Finally, at the moment of exercise of the warrants, a certain “financial dilution” could occur.

Since the warrants will normally only be exercised if the stock exchange price of the shares of the Company at the moment of exercise is higher than the exercise price of the warrants, the holder of the warrants shall normally be able to realize a (hidden) capital gain upon the exercise of the warrants, equal to the difference between the stock exchange price of the share at the moment of exercise of the warrants and the exercise price of the warrants. This difference can be considered a form of financial dilution at the expense of the existing shareholders.

Hereinafter, for illustration purposes only, an example of this potential financial dilution is given. If, in accordance with what is determined in article 6.2 of the issuance conditions of the warrants, the exercise price of the warrants would for instance be equal to (for illustration purposes only) €13.00, then the holder of the warrants will normally only exercise the warrants if the stock exchange price of the shares of the Company is higher than €10.00 at the moment of exercise. Only then, the holder of the warrants will have an immediate financial incentive to exercise the warrants. However, if the stock exchange price of the Company is equal to or lower than €13.00 when the warrants can be exercised, the holder of the warrants will normally not exercise the warrants because no immediate financial gain can be realized upon exercise of the warrants.

It needs to be emphasized that aforementioned example is an illustration only. Furthermore, the illustration is based on the assumption that the warrants can actually be exercised. Furthermore, the taxes that will be due are to be taken into account. It should also be noted that an actual capital gain exists only if it can actually be realized through sale of the acquired shares. An actual capital gain can only be realized by the holder of the warrants if the capital gain which he could realize through sale of the shares acquired is higher than the total sum of the taxes that will be due.

* * *

Done at Ghent, on April 30,2008

On behalf of the board of directors,

By: _____

Thierry Bogaert BVBA,
represented by Thierry Bogaert
Managing Director

By: _____

Pierre Hochuli,
Chairman of the Board of Directors